The psychosis spectrum in Parkinson disease

Nature Reviews Neurology

Volumn 13, Issue 2, 2017, Pages 81-95

  Ffytche, Dominic H ^a   Creese, Byron ^a,b   Politis, Marios ^a   Chaudhuri, K Ray ^a,c   Weintraub, Daniel ^a,d,e   Ballard, Clive ^a,b   Aarsland, Dag ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CLOZAPINE; IOMETOPANE I 123; LEVODOPA; PIMAVANSERIN; QUETIAPINE; RADIOPHARMACEUTICAL AGENT; RIVASTIGMINE; SETOPERONE F 18; TAU PROTEIN; UNCLASSIFIED DRUG;

APOEE4 GENE; ATTENTION; AUDITORY HALLUCINATION; BRAIN BLOOD FLOW; COGNITION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GBA GENE; GENE; GENE MUTATION; HALLUCINATION; HUMAN; JEALOUS DELUSION; LONGITUDINAL STUDY; MAPT GENE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; OLFACTORY HALLUCINATION; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; PARASOMNIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; TACTILE HALLUCINATION; UNIFIED PARKINSON DISEASE RATING SCALE; VERBAL MEMORY; VISION; VISUAL HALLUCINATION; VISUAL ILLUSION; VISUAL MEMORY; PSYCHOLOGY; PSYCHOSIS;

HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 85010002064     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.200     Document Type: Review

References (188)

1. Ravina, B. et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 22, 1061-1068 (2007).
2. Diederich, N. J., Fénelon, G., Stebbins, G. & Goetz, C. G. Hallucinations in Parkinson disease. Nat. Rev. Neurol. 5, 331-342 (2009).
3. Fénelon, G. & Alves, G. Epidemiology of psychosis in Parkinson's disease. J. Neurol. Sci. 289, 12-17 (2010).
4. Rabey, J. M. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat. Disord. 15 (Suppl. 4), S105-S110 (2009).
5. Friedman, J. H. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat. Disord. 16, 553-560 (2010).
6. Friedman, J. H. Parkinson disease psychosis: update. Behav. Neurol. 27, 469-477 (2013).
7. Goetz, C. G. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov. Disord. 25 (Suppl. 1), S104-S109 (2010).
8. Fénelon, G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 13, 18-25 (2008).
9. Inzelberg, R., Kipervasser, S. & Korczyn, A. D. Auditory hallucinations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64, 533-535 (1998).
10. Fénelon, G., Mahieux, F., Huon, R. & Ziegler, M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123, 733-745 (2000).
11. Fénelon, G., Soulas, T., Cleret de Langavant, L., Trinkler, I. & Bachoud-Levi, A. C. Feeling of presence in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 82, 1219-1224 (2011).
12. Wood, R. A., Hopkins, S. A., Moodley, K. K. & Chan, D. Fifty percent prevalence of extracampine hallucinations in Parkinson's disease patients. Front. Neurol. 6, 263 (2015).
13. Boubert, L. & Barnes, J. Phenomenology of visual hallucinations and their relationship to cognitive profile in Parkinson's disease patients: preliminary observations. SAGE Open http://dx.doi. org/10.1177/2158244015585827 (2015).
14. Goetz, C. G., Stebbins, G. T. & Ouyang, B. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov. Disord. 26, 2196-2200 (2011).
15. Goetz, C. G., Fan, W., Leurgans, S., Bernard, B. & Stebbins, G. T. The malignant course of benign hallucinations in Parkinson disease. Arch. Neurol. 63, 713-716 (2006).
16. Chou, K. L. et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin. Neuropharmacol. 28, 215-219 (2005).
17. Papapetropoulos, S. et al. A questionnaire-based (UM?PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol. 8, 21 (2008).
18. Factor, S. A. et al. Cognitive correlates of hallucinations and delusions in Parkinson's disease. J. Neurol. Sci. 347, 316-321 (2014).
19. Moro, A., Munhoz, R. P., Moscovich, M., Arruda, W. O. & Teive, H. A. Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease. Parkinsonism Relat. Disord. 19, 751-754 (2013).
20. Pagonabarraga, J. et al. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov. Disord. 23, 443-448 (2008).
21. Ballard, C. et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am. J. Psychiatry 156, 1039-1045 (1999).
22. Fernandez, H. H. et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov. Disord. 23, 484-500 (2008).
23. Mosimann, U. P. et al. A semi-structured interview to assess visual hallucinations in older people. Int. J. Geriatr. Psychiatry 23, 712-718 (2008).
24. Voss, T. et al. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat. Disord. 19, 295-299 (2013).
25. Yokoi, K. et al. Hallucinators find meaning in noises: pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 56, 245-254 (2014).
26. McKinlay, A. et al. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat. Disord. 14, 37-42 (2008).
27. Fénelon, G., Soulas, T., Zenasni, F. & Cleret de Langavant, L. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov. Disord. 25, 763-766 (2010).
28. Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov. Disord. 31, 45-52 (2016).
29. Friedman, J. H. Editorial on: Pagonabarraga, J. et al. Minor hallucinations occur in drug-naive Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; available from: DOI:10.1002/mds.26432. Mov. Disord. 31, 9-10 (2016).
30. Mack, J. et al. Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am. J. Geriatr. Psychiatry 20, 123-132 (2012).
31. Gibson, G. et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson's disease: a longitudinal 4?year study. Int. J. Geriatr. Psychiatry 28, 626-631 (2013).
32. de la Riva, P., Smith, K., Xie, S. X. & Weintraub, D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83, 1096-1103 (2014).
33. Forsaa, E. B. et al. A 12?year population-based study of psychosis in Parkinson disease. Arch. Neurol. 67, 996-1001 (2010).
34. Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A. & Kragh-Sorensen, P. Prevalence and characteristics of dementia in Parkinson disease: an 8?year prospective study. Arch. Neurol. 60, 387-392 (2003).
35. Anang, J. B. et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 83, 1253-1260 (2014).
36. Uc, E. Y. et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73, 1469-1477 (2009).
37. Morgante, L. et al. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J. Neurol. Neurosurg. Psychiatry 83, 76-82 (2012).
38. Ibarretxe-Bilbao, N. et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J. Neurol. Neurosurg. Psychiatry 81, 650-657 (2010).
39. Ramirez-Ruiz, B., Junque, C., Marti, M. J., Valldeoriola, F. & Tolosa, E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement. Geriatr. Cogn. Disord. 23, 281-288 (2007).
40. Gasca-Salas, C., Clavero, P., Garcia-Garcia, D., Obeso, J. A. & Rodriguez-Oroz, M. C. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. Hum. Brain Mapp. 37, 968-977 (2016).
41. Reijnders, J. S., Ehrt, U., Lousberg, R., Aarsland, D. & Leentjens, A. F. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat. Disord. 15, 379-382 (2009).
42. Rana, A. Q., Vaid, H. M., Edun, A., Dogu, O. & Rana, M. A. Relationship of dementia and visual hallucinations in tremor and non-tremor dominant Parkinson's disease. J. Neurol. Sci. 323, 158-161 (2012).
43. Bodis-Wollner, I. Foveal vision is impaired in Parkinson's disease. Parkinsonism Relat. Disord. 19, 1-14 (2013).
44. Lee, J. Y. et al. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's disease. Mov. Disord. 29, 61-67 (2014).
45. Ramirez-Ruiz, B., Junque, C., Marti, M. J., Valldeoriola, F. & Tolosa, E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov. Disord. 21, 1483-1487 (2006).
46. Shin, S. et al. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 83, 1155-1161 (2012).
47. Barnes, J. & Boubert, L. Visual memory errors in Parkinson's disease patient with visual hallucinations. Int. J. Neurosci. 121, 159-164 (2011).
48. Moustafa, A. A., Krishna, R., Frank, M. J., Eissa, A. M. & Hewedi, D. H. Cognitive correlates of psychosis in patients with Parkinson's disease. Cogn. Neuropsychiatry 19, 381-398 (2014).
49. Ozer, F. et al. Cognitive impairment patterns in Parkinson's disease with visual hallucinations. J. Clin. Neurosci. 14, 742-746 (2007).
50. Katzen, H. et al. Multi-modal hallucinations and cognitive function in Parkinson's disease. Dement. Geriatr. Cogn. Disord. 30, 51-56 (2010).
51. Koerts, J. et al. Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism Relat. Disord. 16, 270-274 (2010).
52. Llebaria, G. et al. Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov. Disord. 25, 2785-2791 (2010).
53. Poletti, M. et al. Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov. Disord. 27, 1679-1682 (2012).
54. Harding, A. J., Broe, G. A. & Halliday, G. M. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125, 391-403 (2002).
55. Gallagher, D. A. et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 134, 3299-3309 (2011).
56. Papapetropoulos, S., McCorquodale, D. S., Gonzalez, J., Jean-Gilles, L. & Mash, D. C. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat. Disord. 12, 253-256 (2006).
57. Jacobson, S. A. et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat. Disord. 20, 1009-1014 (2014).
58. Kalaitzakis, M. E. et al. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat. Disord. 15, 196-204 (2009).
59. Harding, A. J., Stimson, E., Henderson, J. M. & Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125, 2431-2445 (2002).
60. Janzen, J. et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J. Neurol. 259, 147-154 (2012).
61. Oka, H. et al. Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations. Mov. Disord. 22, 1510-1514 (2007).
62. Zhu, K., van Hilten, J. J., Putter, H. & Marinus, J. Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study. Mov. Disord. 28, 755-762 (2013).
63. Lenka, A., Hegde, S., Jhunjhunwala, K. R. & Pal, P. K. Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: a review. Parkinsonism Relat. Disord. 22, 1-8 (2016).
64. Meral, H. et al. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease. Clin. Neurol. Neurosurg. 109, 862-867 (2007).
65. Gama, R. L. et al. Risk factors for visual hallucinations in patients with Parkinson's disease. Neurol. Res. 37, 112-116 (2015).
66. Hirayama, M. et al. Urinary 8?hydroxydeoxyguanosine correlate with hallucinations rather than motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 17, 46-49 (2011).
67. Goetz, C. G. et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50, 515-517 (1998).
68. Dotchin, C. L., Jusabani, A. & Walker, R. W. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat. Disord. 15, 457-460 (2009).
69. Lenka, A., Arumugham, S. S., Christopher, R. & Pal, P. K. Genetic substrates of psychosis in patients with Parkinson's disease: a critical review. J. Neurol. Sci. 364, 33-41 (2016).
70. Papapetropoulos, S. et al. Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci. Lett. 414, 141-144 (2007).
71. Factor, S. A. et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov. Disord. 26, 2190-2195 (2011).
72. de la Fuente-Fernandez, R., Nunez, M. A. & Lopez, E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin. Neuropharmacol. 22, 226-230 (1999).
73. Goetz, C. G. et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch. Neurol. 58, 209-213 (2001).
74. Camicioli, R. et al. Apolipoprotein E ?4 and catechol-O?methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov. Disord. 20, 989-994 (2005).
75. Feldman, B., Chapman, J. & Korczyn, A. D. Apolipoprotein ?4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol. Scand. 113, 14-17 (2006).
76. Monsell, S. E. et al. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. Parkinsonism Relat. Disord. 20, 503-507 (2014).
77. Murray, P. S., Kumar, S., Demichele-Sweet, M. A. & Sweet, R. A. Psychosis in Alzheimer's disease. Biol. Psychiatry 75, 542-552 (2014).
78. Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783-1794 (2009).
79. Oeda, T. et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol. Aging 36, 3306-3313 (2015).
80. Li, Y. et al. Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol. Aging 35, 935.e3-935.e8 (2014).
81. Winder-Rhodes, S. E. et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 136, 392-399 (2013).
82. Creese, B. et al. Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. Am. J. Geriatr. Psychiatry 22, 580-586 (2014).
83. Kiferle, L. et al. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5?HT2A receptor and transporter genes. Neurosci. Lett. 422, 228-231 (2007).
84. Andreassen, O. A. et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry 20, 207-214 (2015).
85. Desikan, R. S. et al. Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol. Psychiatry 20, 1588-1595 (2015).
86. Nho, K. et al. Comprehensive gene-and pathwaybased analysis of depressive symptoms in older adults. J. Alzheimers Dis. 45, 1197-1206 (2015).
87. Onofrj, M. et al. Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behav. Neurol. 27, 479-493 (2013).
88. Diederich, N. J., Goetz, C. G. & Stebbins, G. T. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov. Disord. 20, 130-140 (2005).
89. Collerton, D., Perry, E. & McKeith, I. Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav. Brain Sci. 28, 737-757 (2005).
90. Shine, J. M., Halliday, G. M., Naismith, S. L. & Lewis, S. J. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov. Disord. 26, 2154-2159 (2011).
91. Shine, J. M., O'Callaghan, C., Halliday, G. M. & Lewis, S. J. Tricks of the mind: visual hallucinations as disorders of attention. Prog. Neurobiol. 116, 58-65 (2014).
92. Muller, A. J., Shine, J. M., Halliday, G. M. & Lewis, S. J. Visual hallucinations in Parkinson's disease: theoretical models. Mov. Disord. 29, 1591-1598 (2014).
93. Shine, J. M. et al. Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson's disease and visual hallucinations. Proc. Biol. Sci. 282, 20142047 (2015).
94. Shine, J. M., Halliday, G. H., Carlos, M., Naismith, S. L. & Lewis, S. J. Investigating visual misperceptions in Parkinson's disease: a novel behavioral paradigm. Mov. Disord. 27, 500-505 (2012).
95. Shine, J. M. et al. The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum. Brain Mapp. 35, 2206-2219 (2014).
96. Yao, N. et al. The default mode network is disrupted in Parkinson's disease with visual hallucinations. Hum. Brain Mapp. 35, 5658-5666 (2014).
97. Botha, H. & Carr, J. Attention and visual dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 18, 742-747 (2012).
98. Carter, R. & ffytche, D. H. On visual hallucinations and cortical networks: a trans-diagnostic review. J. Neurol. 262, 1780-1790 (2015).
99. Lenka, A., Jhunjhunwala, K. R., Saini, J. & Pal, P. K. Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: a critical review. Parkinsonism Relat. Disord. 21, 683-691 (2015).
100. Ibarretxe-Bilbao, N., Junque, C., Marti, M. J. & Tolosa, E. Cerebral basis of visual hallucinations in Parkinson's disease: structural and functional MRI studies. J. Neurol. Sci. 310, 79-81 (2011).
101. Goldman, J. G. et al. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain 137, 849-859 (2014).
102. Ramirez-Ruiz, B. et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur. J. Neurol. 14, 750-756 (2007).
103. Watanabe, H. et al. Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination. Mov. Disord. 28, 1732-1736 (2013).
104. Meppelink, A. M., de Jong, B. M., Teune, L. K. & van Laar, T. Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations. Mov. Disord. 26, 142-147 (2011).
105. Pagonabarraga, J. et al. Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 20, 290-296 (2014).
106. Ibarretxe-Bilbao, N. et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J. Neurol. 255, 1324-1331 (2008).
107. Sanchez-Castaneda, C. et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov. Disord. 25, 615-622 (2010).
108. Gama, R. L. et al. Structural brain abnormalities in patients with Parkinson's disease with visual hallucinations: a comparative voxel-based analysis. Brain Cogn. 87, 97-103 (2014).
109. Kraft, E., Winkelmann, J., Trenkwalder, C. & Auer, D. P. Visual hallucinations, white matter lesions and disease severity in Parkinson's disease. Acta Neurol. Scand. 99, 362-367 (1999).
110. Zhong, J. et al. Why psychosis is frequently associated with Parkinson's disease? Neural Regen. Res. 8, 2548-2556 (2013).
111. Ravina, B. et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov. Disord. 27, 1392-1397 (2012).
112. Ballanger, B. et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 67, 416-421 (2010).
113. Huot, P. et al. Increased levels of 5?HT1A receptor binding in ventral visual pathways in Parkinson's disease. Mov. Disord. 27, 735-742 (2012).
114. Minoshima, S. et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann. Neurol. 50, 358-365 (2001).
115. Lobotesis, K. et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56, 643-649 (2001).
116. Firbank, M. J., Lloyd, J. & O'Brien, J. T. The relationship between hallucinations and FDG-PET in dementia with Lewy bodies. Brain Imaging Behav. 10, 636-639 (2015).
117. Boecker, H. et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch. Neurol. 64, 984-988 (2007).
118. Nagano-Saito, A. et al. Visual hallucination in Parkinson's disease with FDG PET. Mov. Disord. 19, 801-806 (2004).
119. Park, H. K. et al. Visual hallucinations and cognitive impairment in Parkinson's disease. Can. J. Neurol. Sci. 40, 657-662 (2013).
120. Okada, K., Suyama, N., Oguro, H., Yamaguchi, S. & Kobayashi, S. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J. Neurol. 246, 365-368 (1999).
121. Oishi, N. et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65, 1708-1715 (2005).
122. Goetz, C. G., Vaughan, C. L., Goldman, J. G. & Stebbins, G. T. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov. Disord. 29, 115-117 (2014).
123. ffytche, D. H. The hodology of hallucinations. Cortex 44, 1067-1083 (2008).
124. Kataoka, H., Furiya, Y., Morikawa, M., Ueno, S. & Inoue, M. Increased temporal blood flow associated with visual hallucinations in Parkinson's disease with dementia. Mov. Disord. 23, 464-465 (2008).
125. Stebbins, G. T. et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 63, 1409-1416 (2004).
126. Meppelink, A. M. et al. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain 132, 2980-2993 (2009).
127. Holroyd, S. & Wooten, G. F. Preliminary FMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. J. Neuropsychiatry Clin. Neurosci. 18, 402-404 (2006).
128. Ramírez-Ruiz, B. et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov. Disord. 23, 2335-2343 (2008).
129. Yao, N. et al. Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations. Parkinsonism Relat. Disord. 21, 131-137 (2015).
130. Matsui, H. et al. The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin. Neuropharmacol. 28, 79-82 (2005).
131. Kurita, A., Murakami, M., Takagi, S., Matsushima, M. & Suzuki, M. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov. Disord. 25, 167-171 (2010).
132. Onofrj, M. et al. Visual hallucinations in Parkinson's disease: clues to separate origins. J. Neurol. Sci. 248, 143-150 (2006).
133. Onofrj, M. et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8?year follow?up. Neurol. Sci. 23 (Suppl. 2), S91-S94 (2002).
134. Manganelli, F. et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 132, 2350-2355 (2009).
135. Seppi, K. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S42-S80 (2011).
136. Pollak, P. et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry 75, 689-695 (2004).
137. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757-763 (1999).
138. Wolters, E. C. et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40, 832-834 (1990).
139. Ondo, W. G., Tintner, R., Voung, K. D., Lai, D. & Ringholz, G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov. Disord. 20, 958-963 (2005).
140. Shotbolt, P., Samuel, M., Fox, C. & David, A. S. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr. Dis. Treat. 5, 327-332 (2009).
141. Kurlan, R., Cummings, J., Raman, R., Thal, L. & Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68, 1356-1363 (2007).
142. Ondo, W. G., Levy, J. K., Vuong, K. D., Hunter, C. & Jankovic, J. Olanzapine treatment for dopaminergicinduced hallucinations. Mov. Disord. 17, 1031-1035 (2002).
143. Goetz, C. G., Blasucci, L. M., Leurgans, S. & Pappert, E. J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55, 789-794 (2000).
144. Weintraub, D. et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 73, 535-541 (2016).
145. Ballard, C. et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J. Am. Med. Dir. Assoc. 16, 898.e1-898.e7 (2015).
146. Meltzer, H. Y. et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35, 881-892 (2010).
147. Cummings, J. et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebocontrolled phase 3 trial. Lancet 383, 533-540 (2014).
148. Borgemeester, R. W., Lees, A. J. & van Laar, T. Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat. Disord. 27, 35-40 (2016).
149. van Laar, T., Postma, A. G. & Drent, M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and preexisting visual hallucinations. Parkinsonism Relat. Disord. 16, 71-72 (2010).
150. Geerligs, L., Meppelink, A. M., Brouwer, W. H. & van Laar, T. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. Clin. Neuropharmacol. 32, 266-268 (2009).
151. Pietz, K., Hagell, P. & Odin, P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatry 65, 709-716 (1998).
152. Martinez-Martin, P. et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov. Disord. 30, 510-516 (2015).
153. Todorova, A. & Ray Chaudhuri, K. Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 19, 1073-1078 (2013).
154. Ueda, S., Koyama, K. & Okubo, Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J. ECT 26, 111-115 (2010).
155. Usui, C. et al. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1704-1708 (2011).
156. Chaudhuri, K. R. & Fung, V. S. Fast Facts: Parkinson's Disease 4th edn (Health Press Limited, 2016).
157. ffytche, D. H. Visual hallucinatory syndromes: past, present, and future. Dialogues Clin. Neurosci. 9, 173-189 (2007).
158. ffytche, D. H. Visual hallucinations in eye disease. Curr. Opin. Neurol. 22, 28-35 (2009).
159. Ebersbach, G. An artist's view of drug-induced hallucinosis. Mov. Disord. 18, 833-834 (2003).
160. Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Mov. Disord. 26, 2387-2395 (2011).
161. Diederich, N. J., Stebbins, G., Schiltz, C. & Goetz, C. G. Are patients with Parkinson's disease blind to blindsight? Brain 137, 1838-1849 (2014).
162. Santhouse, A. M., Howard, R. J. & ffytche, D. H. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 123, 2055-2064 (2000).
163. Ettinger, U. et al. Decomposing the neural correlates of antisaccade eye movements using event-related FMRI. Cereb. Cortex 18, 1148-1159 (2008).
164. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
165. De Marco, E. V. et al. Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov. Disord. 23, 460-463 (2008).
166. Creese, B. et al. No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. Neurosci. Lett. 531, 1-4 (2012).
167. Kaiser, R. et al. l?Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60, 1750-1755 (2003).
168. Wang, J., Zhao, C., Chen, B. & Liu, Z. L. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. Neurosci. Lett. 355, 193-196 (2004).
169. Schumacher-Schuh, A. F. et al. Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. Int. J. Neuropsychopharmacol. 16, 1251-1258 (2013).
170. Makoff, A. J. et al. Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics 10, 43-48 (2000).
171. Fujii, C. et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin. Genet. 56, 394-399 (1999).
172. Wang, J., Si, Y. M., Liu, Z. L. & Yu, L. Cholecystokinin, cholecystokinin?A receptor and cholecystokinin?B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics 13, 365-369 (2003).
173. Goldman, J. G., Goetz, C. G., Berry-Kravis, E., Leurgans, S. & Zhou, L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch. Neurol. 61, 1280-1284 (2004).
174. Goldman, J. G. et al. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov. Disord. 26, 1781-1782 (2011).
175. Lin, J. J., Yueh, K. C., Lin, S. Z., Harn, H. J. & Liu, J. T. Genetic polymorphism of the angiotensin converting enzyme and l?dopa-induced adverse effects in Parkinson's disease. J. Neurol. Sci. 252, 130-134 (2007).
176. Pascale, E. et al. Genetic polymorphism of angiotensinconverting enzyme is not associated with the development of Parkinson's disease and of l?dopainduced adverse effects. J. Neurol. Sci. 276, 18-21 (2009).
177. Schumacher-Schuh, A. F. et al. Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients. Pharmacogenomics J. 14, 289-294 (2014).
178. De Luca, V. et al. HOMER1 promoter analysis in Parkinson's disease: association study with psychotic symptoms. Neuropsychobiology 59, 239-245 (2009).
179. Nebe, A. & Ebersbach, G. Selective diplopia in Parkinson's disease: a special subtype of visual hallucination? Mov. Disord. 22, 1175-1178 (2007).
180. Urwyler, P. et al. Visual complaints and visual hallucinations in Parkinson's disease. Parkinsonism Relat. Disord. 20, 318-322 (2014).
181. Meppelink, A. M., Koerts, J., Borg, M., Leenders, K. L. & van Laar, T. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Mov. Disord. 23, 1906-1912 (2008).
182. Barnes, J. & Boubert, L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J. Neurol. Neurosurg. Psychiatry 79, 190-192 (2008).
183. Imamura, K., Wada-Isoe, K., Kitayama, M. & Nakashima, K. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol. Scand. 117, 255-259 (2008).
184. Grossi, D. et al. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int. J. Geriatr. Psychiatry 20, 668-673 (2005).
185. Chung, E. J., Seok, K. & Kim, S. J. A comparison of montreal cognitive assessment between patients with visual hallucinations and without visual hallucinations in Parkinson's disease. Clin. Neurol. Neurosurg. 130, 98-100 (2015).
186. Breier, A. et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psychiatry 52, 438-445 (2002).
187. Burn, D. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. 21, 1899-1907 (2006).
188. Aarsland, D. et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 8, 613-618 (2009).